Millipore Sigma Vibrant Logo

371970 HA 1077, Dihydrochloride - CAS 103745-39-7 - Calbiochem

A cell-permeable, reversible, and ATP-competitive Ca2+ antagonist with anti-vasospastic properties.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Fasudil, (5-Isoquinolinesulfonyl)homopiperazine, 2HCl, PKG Inhibitor VII

Primary Target: PKA
View Products on Sigmaaldrich.com
371970
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
103745-39-7C₁₄H₁₇N₃O₂S · 2HCl

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
371970-1MGCN
Retrieving availability...
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewA cell-permeable, reversible, and ATP-competitive Ca2+ antagonist with anti-vasospastic properties. Inhibits protein kinase A (Ki = 1.6 µM), protein kinase G (Ki = 1.6 µM), and myosin light chain kinase (Ki = 36 µM). Also reported to potently inhibit Rho-associated kinase (ROCK; IC50 = 10.7 µM). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency.
      Catalogue Number371970
      Brand Family Calbiochem®
      SynonymsFasudil, (5-Isoquinolinesulfonyl)homopiperazine, 2HCl, PKG Inhibitor VII
      References
      ReferencesWatanabe, K., et al. 2007. Nature Biotech. 25, 681.
      Swärd, K., et al. 2000. J. Physiol. 522, 33.
      Takizawa, S., et al. 1993. Eur. J. Pharmacol. 250, 431.
      Seto, M., et al. 1991. Eur. J. Pharmacol. 195, 267.
      Shirotani, M., et al. 1991. J. Pharmacol. Exp. Ther. 259, 738.
      Asano, T., et al. 1990. Eur. J. Pharmacol. 190, 365.
      Sasaki, Y., and Sasaki, Y. 1990. Biochem. Biophys. Res. Commun. 171, 1182.
      Asano, T., et al. 1989. Br. J. Pharmacol. 98, 1091.
      Product Information
      CAS number103745-39-7
      ATP CompetitiveY
      FormWhite solid
      Hill FormulaC₁₄H₁₇N₃O₂S · 2HCl
      Chemical formulaC₁₄H₁₇N₃O₂S · 2HCl
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetPKA
      Primary Target IC<sub>50</sub>10.7 µM inhibiting Rho-associated kinase (ROCK)
      Primary Target K<sub>i</sub>.6 µM, 1.6 µM, 36 µM, inhibiting protein kinase A, protein kinase G, myosin light chain kinase, respectively
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 20/21/22

      Harmful by inhalation, in contact with skin and if swallowed.
      S PhraseS: 36

      Wear suitable protective clothing.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful
      Storage +2°C to +8°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, refrigerate (4°C). Aqueous stock solutions are stable for up to 6 months at 4°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      371970-1MGCN 04055977213539

      Documentation

      HA 1077, Dihydrochloride - CAS 103745-39-7 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      HA 1077, Dihydrochloride - CAS 103745-39-7 - Calbiochem Certificates of Analysis

      TitleLot Number
      371970

      References

      Reference overview
      Watanabe, K., et al. 2007. Nature Biotech. 25, 681.
      Swärd, K., et al. 2000. J. Physiol. 522, 33.
      Takizawa, S., et al. 1993. Eur. J. Pharmacol. 250, 431.
      Seto, M., et al. 1991. Eur. J. Pharmacol. 195, 267.
      Shirotani, M., et al. 1991. J. Pharmacol. Exp. Ther. 259, 738.
      Asano, T., et al. 1990. Eur. J. Pharmacol. 190, 365.
      Sasaki, Y., and Sasaki, Y. 1990. Biochem. Biophys. Res. Commun. 171, 1182.
      Asano, T., et al. 1989. Br. J. Pharmacol. 98, 1091.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision08-January-2010 RFH
      SynonymsFasudil, (5-Isoquinolinesulfonyl)homopiperazine, 2HCl, PKG Inhibitor VII
      DescriptionA cell-permeable, reversible, and ATP-competitive Ca2+ antagonist with anti-vasospastic properties. Inhibits protein kinase A (Ki = 1.6 µM), protein kinase G (Ki = 1.6 µM), and myosin light chain kinase (Ki = 3.6 µM). Also reported to potently inhibit Rho-associated kinase (ROCK; IC50 = 10.7 µM). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency.
      FormWhite solid
      CAS number103745-39-7
      Chemical formulaC₁₄H₁₇N₃O₂S · 2HCl
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityH₂O (1 mg/ml)
      Storage +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, refrigerate (4°C). Aqueous stock solutions are stable for up to 6 months at 4°C.
      Toxicity Harmful
      ReferencesWatanabe, K., et al. 2007. Nature Biotech. 25, 681.
      Swärd, K., et al. 2000. J. Physiol. 522, 33.
      Takizawa, S., et al. 1993. Eur. J. Pharmacol. 250, 431.
      Seto, M., et al. 1991. Eur. J. Pharmacol. 195, 267.
      Shirotani, M., et al. 1991. J. Pharmacol. Exp. Ther. 259, 738.
      Asano, T., et al. 1990. Eur. J. Pharmacol. 190, 365.
      Sasaki, Y., and Sasaki, Y. 1990. Biochem. Biophys. Res. Commun. 171, 1182.
      Asano, T., et al. 1989. Br. J. Pharmacol. 98, 1091.

      Related Products & Applications

      Categories

      Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > Protein Phosphorylation / Dephosphorylation > Protein Kinase A (PKA; cAMP-Dependent Protein Kinase) Inhibitors
      Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > Protein Phosphorylation / Dephosphorylation > Protein Kinase G (PKG; cGMP-Dependent Protein Kinase) Inhibitors
      Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > Protein Phosphorylation / Dephosphorylation > Rho Kinase (ROCK) Inhibitors